VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC/ US92532F1003 /
VRTX
15/11/2024 17:32:14
|
Diferencia
-26.90
|
Volumen |
Bid17:32:14 |
Ask17:32:14 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
437.35EUR
|
-5.79%
|
25 Volumen de negocios: 11,368.15 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
113.92 mil millonesEUR |
- |
- |
Descripción de negocio
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Consejo de gestión & Consejo de supervisión
CEO |
Reshma Kewalramani, M.D. |
Consejo de gestión |
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D. |
Consejo de supervisión |
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay |
Datos de la empresa
Nombre: |
Vertex Pharmaceuticals Inc. |
Dirección: |
50 Northern Avenue,Boston, Massachusetts 02210, USA |
Teléfono: |
+1-617-961-7163 |
Fax: |
- |
E-mail: |
Investorinfo@VRTX.com
|
Internet: |
www.vrtx.com/ |
Industria: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Subsector: |
Pharmaceuticals |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
82.70% |
Fecha de OPI: |
24/07/1991 |
Relación con inversores
Nombre: |
Susie Lisa |
IR teléfono: |
+1-617-341-6108 |
IR-fax: |
- |
IR e-mail: |
investorinfo@vrtx.com
|
Accionistas mayoritarios
Otros |
|
53.31% |
Vanguard Group |
|
8.63% |
BlackRock Inc. |
|
8.48% |
Capital World Investors |
|
8.45% |
FMR LLC. |
|
5.03% |
State Street Corporation |
|
4.68% |
ALLIANCEBERNSTEIN L P |
|
2.73% |
PRICE T ROWE ASSOCIATES INC MD |
|
2.28% |
GEODE CAPITAL MANAGEMENT LLC |
|
2.20% |
Otros |
|
4.21% |